Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Pseudobulbar Affect is a condition characterized by frequent episodes of laughing and crying
out of proportion. Other terms used to describe this condition include emotional lability,
emotionalism, emotion incontinence, emotional discontrol, excessive emotionalism and
pathological laughing and crying. AVP-923 is a new experimental drug that may assist in the
reduction of uncontrolled episodes. This study will test the safety and efficacy of AVP-923
in the treatment of MS patients suffering from pseudobulbar affect.